BiotechTube

SAGE-547

Phase 1/2Completed
0 views this week 0 watching💤 Quiet
Interest: 26/100
26
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Super-refractory Status Epilepticus

Conditions

Super-refractory Status Epilepticus

Trial Timeline

Mar 21, 2014 → May 3, 2015

NCT ID
NCT02052739

About SAGE-547

SAGE-547 is a phase 1/2 stage product being developed by Supernus Pharmaceuticals for Super-refractory Status Epilepticus. The current trial status is completed. This product is registered under clinical trial identifier NCT02052739. Target conditions include Super-refractory Status Epilepticus.

What happened to similar drugs?

0 of 1 similar drugs in Super-refractory Status Epilepticus were approved

Approved (0) Terminated (0) Active (1)
🔄SAGE-547 + PlaceboSupernus PharmaceuticalsPhase 3

Hype Score Breakdown

Clinical
9
Activity
8
Company
9
Novelty
0
Community
0

Clinical Trials (3)

NCT IDPhaseStatus
NCT02433314Pre-clinicalCompleted
NCT02285504Phase 2Completed
NCT02052739Phase 1/2Completed

Competing Products

2 competing products in Super-refractory Status Epilepticus

See all competitors
ProductCompanyStageHype Score
SAGE-547Supernus PharmaceuticalsPre-clinical
20
SAGE-547 + PlaceboSupernus PharmaceuticalsPhase 3
34